In breast cancer (Fig. 7A–C), high CT83 expression is statistically associated with poor OS (overall survival; HR = 1.72, 95% CI 1.24–2.37, p = 0.00, N = 626) but not with RFS (relapse-free survival; HR = 0.86, 95% CI 0.73–1.00, p = 0.06, N = 1764) and DMFS (distant metastasis-free survival; HR = 1.46, 95% CI: 0.99–2.16, p = 0.06, N = 664) in the overall analysis. This evidence concerns the gene CT83 and breast cancer.